315
Views
2
CrossRef citations to date
0
Altmetric
Meta-Analysis

The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis

, , , &
Pages 1233-1242 | Received 24 May 2022, Accepted 29 Aug 2022, Published online: 07 Sep 2022
 

ABSTRACT

Background

Dupilumab is approved for multiple type 2 inflammatory diseases. In the treatment procedure, the changes of IgE levels need further analysis. We evaluated the changes of IgE levels through meta-analysis, aiming to provide a more comprehensive result.

Research design and methods

Databases were searched to select eligible publications. After being included, study quality was assessed. The standardized mean difference (SMD) was used as an evaluation.

Results

Seven studies were included. At week 4, the level of IgE did not decrease significantly, with SMD = −0.12 (95%CI: −0.31, 0.07) (P > 0.05). At week 8, 12, 16, 24, and 52, the level of IgE decreased significantly, which was SMD = −0.26 (95%CI: −0.48, −0.03); −0.25 (95%CI: −0.32, −0.18); −0.49 (95%CI: −0.65, −0.33); −0.30 (95%CI: −0.38, −0.22); −0.40 (95%CI: −0.48, −0.32) (P < 0.05). In AD studies, with the increase of IgE levels, due to the decrease in the total dose of dupilumab, the efficacy index showed a decreasing trend.

Conclusions

Levels of IgE can be significantly decreased in patients with dupilumab treatment. In AD patients, the efficacy was related to total dose; for patients with high IgE levels, efficacy may be better with the dose increased.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

B Zhou made a significant contribution to the conception, study design, execution, acquisition of data, analysis and interpretation and have drafted and written the article. J Dong made a significant contribution to the conception, study design, execution, acquisition of data, analysis and interpretation and have written the article. S Liang made a significant contribution to the execution, acquisition of data, analysis and interpretation and have drafted the article. S Shang made a significant contribution to the execution, acquisition of data, analysis and interpretation and have drafted article. L Li made a significant contribution to the conception, study design, execution, acquisition of data, analysis and interpretation and have substantially revised and critically reviewed the article. All authors have agreed on the journal to which the article submitted. All authors reviewed and agreed on all versions of the article before submission, during revision, the final version accepted for publication, and any significant changes introduced at the proofing stage. All authors agree to take responsibility and be accountable for the contents of the article and to share responsibility to resolve any questions raised about the accuracy or integrity of the published work.

Supplemental data

Supplemental data for this article can be accessed online at https://doi.org/10.1080/17512433.2022.2120469.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.